Close Menu

You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.

Home » Business, Policy & Funding » Business News » Cowen, SVB Leerink Initiate Coverage of 908 Devices With Outperform Ratings

Cowen, SVB Leerink Initiate Coverage of 908 Devices With Outperform Ratings

Jan 12, 2021
|
staff reporter

NEW YORK – Investment banks Cowen and SVB Leerink said on Tuesday they have initiated coverage of miniature mass spectrometry firm 908 Devices, both with an Outperform rating, and SVB Leerink with a price target of $70 per share.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

The Scan

Germany to Increase Viral Sequencing

Reuters reports that Germany is seeking to sequence 5 percent of patient samples that test positive for SARS-CoV-2.

Getting Used to It

23andMe and Medscape say primary care physicians are increasingly more comfortable with discussing direct-to-consumer genetic testing results.

Green Access at Science

The publisher of the Science family of journals will allow some authors to place peer-reviewed versions of their papers into publicly accessible repositories.

Science Papers Examine Chronic Kidney Disease GWAS, Pneumonia Microbiome

In Science this week: analysis of genome-wide association studies of chronic kidney disease, and more.

What's Popular?

In Business News

  1. Bionano Genomics Stock Soars on User Presentations, Public Stock Offering, Renewed Nasdaq Compliance

  2. Ancestry to Discontinue NGS-Based AncestryHealth Service

  3. Pacific Biosciences CEO Discusses Q4 Results, New Sequencing Platforms at JP Morgan

  4. JP Morgan Healthcare Conference 2021, Day 3: Exact Sciences, Danaher, NanoString, Bio-Techne, More

  5. People in the News: Broad Institute's Eric Lander Named White House Science Advisor; More

Sponsorships

Privacy Policy.  Terms & Conditions.  .  Copyright © 2021 GenomeWeb, a business unit of Crain Communications.  All Rights Reserved.